Peptide Knowledge Base · Longevity
DSIP (Emideltide): what it is, what the evidence says, and its real status
Delta-sleep-inducing peptide, studied for sleep quality and stress.
Short version: a sleep-associated peptide with an evocative name and a thin, dated evidence base. On the FDA review agenda, a waitlist, not a sleep aid you can get.
Can you actually get it?
Plain-English verdict: Waitlist.
Regulatory status: Under PCAC review · PCAC · Jul 23–24, 2026.
Not available to prescribe today. On the PCAC agenda; the human evidence is older and limited, so it stays education and waitlist only.
How does DSIP (Emideltide) work?
A nine-amino-acid peptide first isolated in studies of sleep regulation; mechanism in humans is poorly characterized.
What it does — and what it does not do
What it does: Studied, mostly in older work, for sleep and stress-resilience interest.
What it does not do: It is not a proven sleep medication, and it is not available to prescribe today.
How honest is the evidence?
Evidence grade D — preclinical or animal-dominant; no controlled human efficacy data. Read our grading methodology for what each grade means.
What we still don't know: Modern controlled human evidence is scarce; effect on sleep architecture is unconfirmed.
WADA status: Not prohibited.
How it is taken
No established human clinical dosing; research-stage.
Who should not take it
Not characterized in humans; not a substitute for evaluation of a sleep disorder.
Sources
Older DSIP sleep-regulation literature (limited modern replication) · FDA PCAC docket, Jul 2026
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.